BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37269870)

  • 1. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
    François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
    Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
    François B; Lambden S; Garaud JJ; Derive M; Grouin JM; Asfar P; Darreau C; Mira JP; Quenot JP; Lemarié J; Mercier E; Lacherade JC; Vinsonneau C; Fivez T; Helms J; Badie J; Levy M; Cuvier V; Salcedo-Magguilli M; Laszlo-Pouvreau AL; Laterre PF; Gibot S;
    EClinicalMedicine; 2023 Jun; 60():102013. PubMed ID: 37350989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
    Francois B; Lambden S; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Grouin JM; Garaud JJ; Salcedo-Magguilli M; Levy M; Laterre PF
    BMJ Open; 2021 Jul; 11(7):e042921. PubMed ID: 34233965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
    François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
    Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
    François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
    Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
    Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies.
    Theobald V; Schmitt FCF; Middel CS; Gaissmaier L; Brenner T; Weigand MA
    Crit Care; 2024 Jan; 28(1):17. PubMed ID: 38191420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
    Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
    Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.